ATILA Project: Aspirin Versus Tirofiban in Endovascular Treatment for Patients With Acute Ischemic Stroke Due to Tandem Lesion

NCT05225961 | Active Not Recruiting Phase 4

• 1 other identifier: ATILA-ictus-2021
• Study Type: interventional
• Target: 240
• Locations: 1 country
• Sites: 13

Brief Summary

Patients with tandem lesions (TL) are defined as patients with an acute ischemic stroke (AIS) with occlusion of an intracranial vessel of the anterior circulation and an occlusion or severe stenosis (70-99%) of the origin of the ipsilateral internal carotid artery (ICA). The greatest current limitation in the management of this type of lesion is the use of antithrombotic medication (double antiaggregation) in the acute phase that is required in case of placing extracranial stent to stabilize the atheroma plaque. In relation to this antiplatelet regimen, the latest clinical practice guidelines warn about the risk of combining intravenous fibrinolysis with antiplatelet medication in the acute phase, since it seems to increase the risk of symptomatic intracranial hemorrhage (sICH). However, the non-stabilization of the carotid atheroma plaque is associated with higher rates of cervical reocclusion, poorer functional prognosis, and higher mortality. Therefore, the use of a single antiplatelet agent could be a reasonable alternative. To establish the best protocol for mono-antiaggregant therapy in the acute phase of TL, the investigators propose to carry out a prospective multicenter randomized clinical trial.

1. 1.All patients with ischemic stroke secondary to TL in the anterior circulation candidates for mechanical thrombectomy in whom cervical endoprosthesis will be placed in the acute phase, will be included, randomized to two groups: 500 mg of intravenous (iv) Aspirin vs Low dose regimen of Tirofiban iv.
2. 2.Carotid reocclusion rates and sICH rates will be evaluated within the first 24 hours after mechanical thrombectomy . As a secondary objective, the functional prognosis at 3 months in both groups will be analyzed, as well as a panel of biomarkers predictors of reocclusion in both groups. Establishing an antiplatelet management protocol in the acute phase in these patients would be an innovative strategy not developed by any other group worldwide, and would place us at the forefront of research in the field. Likewise, developing a clinical-biological predictive model of carotid reocclusion will allow us to establish risk patients in which to plan alternative treatments. Reference hospitals in the treatment of ischemic stroke at the national level with sufficient experience in the management of this pathology will participate in the project.

Conditions

Acute Ischemic Stroke

Keywords

Ischemic Stroke; Tandem Lesion; Tirofiban; Stent; Mechanical thrombectomy

Outcome Measures

Primary Outcomes (3)

• Carotid Reocclusion

  Outcome measure assessment will be performed using ultrasound doppler, in which carotid reocclusion is define by: * the presence at the level of the occlusion point, by a characteristic biphasic, brief and low speed pattern both in the Doppler spectrum and in color mode (color image with both orthodromic and antidromic flow, red-blue just proximal to the occlusion. * An anechoic appearance with a false appearance of permeable light, detecting the absence of flow in color and Doppler modes.

  Annually (single evaluation): within the first 24 hours (+/- 12hours)

• Platelet aggregation phenomena

  Outcome measure assessment will be performed using ultrasound doppler, in which carotid reocclusion is define by: * the presence at the level of the occlusion point, by a characteristic biphasic, brief and low speed pattern both in the Doppler spectrum and in color mode (color image with both orthodromic and antidromic flow, red-blue just proximal to the occlusion. * An anechoic appearance with a false appearance of permeable light, detecting the absence of flow in color and Doppler modes

  Annually (single evaluation): within the first 24 hours (+/- 12hours)

• Symptomatic intracranial hemorrhage (sICH)

  The sICH is defined as a new intracranial hemorrhage in brain computerized tomography within hospitalization related to an National institute of Health Stroke Scale score increase \>4 points compared with stroke admission.

  Within first 24 hours after inclusion

Secondary Outcomes (1)

• Good functional prognosis

  At 90 days (+/- 7 days) after inclusion

Study Arms (2)

Tirofiban

EXPERIMENTAL

An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 10 ml (500 micrograms) of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters).

Drug: Tirofiban

Acetylsalicylic acid

ACTIVE COMPARATOR

A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. One vial of ASPIRINA ® in not more than 250 ml in 0.9% sodium chloride solution, 5% and 10% glucose solution, Ringer's solution or lactated Ringer's. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial.

Drug: Acetylsalicylic acid

Interventions

Tirofiban DRUG

An intravenous bolus of 500 micrograms of Tirofiban will be intravenously administered in five minutes with an infusion pump (infusion rate: 120 milliliters / hour), which is equivalent to 500 micrograms of Tirofiban. After five minutes, a dose reduction will be programmed to 200 micrograms / hour (infusion rate: 4 milliliters / hour for 24 hours (maximum total infused dose of 96 milliliters). Tirofiban infusion started in the neuroradiology room should be maintained until a control brain computerized tomography (CT) scan is performed at 20 hours (+/-2 hours). Once the absence of parenchymal hematoma is demonstrated in control CT, loading doses of acetylsalicylic acid and clopidogrel will be intravenously administered in the Tirofiban group, and the perfusion must be maintained simultaneously of Tirofiban and oral double antiplatelet therapy for four hours, after which the administration of the experimental drug should be discontinued.

Tirofiban

Acetylsalicylic acid DRUG

A single dose 500 milligrams of Acetylsalicylic acid (ASPIRINA®, 500 mg) will be intravenously administered. The solution for injection should be prepared on the spot and used immediately after preparation. It is highly recommended to administer as soon as possible after femoral puncture and always before stent placement, allowing a 10-minute delay after placement of the cervical endoprosthesis. In case of exceeding this time, the patient will be withdrawn from the trial. It will not be necessary to maintain aspirin infusion. In the Acetylsalicylic acid group, a head computerized tomography scan will also be performed at 20 (+/- 2 hours) after the endovascular procedure. Once the absence of parenchymal hematoma is demonstrated, a load of clopidogrel and 100 mg of Acetylsalicylic acid will be administered. Oral antiplatelet medication can be administered orally if the patient has a good level of consciousness and is not associated with dysphagia; or by placing a nasogastric tube.

Acetylsalicylic acid

Eligibility Criteria

• Age: 18 Years - 100 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with acute ischemic stroke of the anterior territory secondary to a tandem lesion, with an indication for thrombectomy treatment according to the current recommendations of the Clinical Practice Guidelines, and the need for cervical stent placement.
• The intracranial occlusion locations that may be included are: carotid "T", M1 and M2 segments of the middle cerebral artery, segment A1 of the anterior cerebral artery; and in the case that the posterior cerebral artery has fetal origin and is the site of intracranial occlusion.
• ASPECTS (Alberta Stroke Program Early computerized Tomography Score) ≥6.
• Greater than or equal to 18 years of age.
• Signed informed consent.

You may not qualify if:

• Patients under 18 years of age.
• Patients with ASPECTS \<6.
• Bilateral strokes or those produced by simultaneous occlusion of an artery in the anterior and posterior territory.
• Patients whose carotid stenosis is due to a re-stenosis or reocclusion of a pre-existing cervical stent.
• Candidate patients for carotid puncture.
• Severe comorbidity and / or reduced life expectancy.
• Modified Rankin scale (mRS)\> 2.
• Severe allergy to contrast medium.
• Pregnant.
• Patients with intracranial occlusive arteriosclerotic disease or extra or intracranial dissection.
• Documented allergy to acetylsalicylic acid or Tirofiban.
• Personal history of platelet penia (Platelets \<100,000)
• Concomitant anticoagulant treatment with presence of International Normalized Ratio (INR) \> 1.7 in case of anti-vitamin K treatment or taking direct oral anticoagulant \<48 hours ago)
• Medical history of the patient that carries a high risk of bleeding according to the investigator's criteria.

Sponsors & Collaborators

• Fundación Pública Andaluza para la gestión de la Investigación en Sevilla: lead

Study Sites (13)

Complexo Hospitalario Universitario A Coruña

A Coruña, A Coruña, Spain

Location

General Hospital Dr. Balmis (Alicante)

Alicante, Alicante, Spain

Location

Complejo Hospitalario Torrecárdenas

Almería, Almería, Spain

Location

Complejo Hospital Universitario de Badajoz

Badajoz, Badajoz, Spain

Location

Germans Trias i Pujol Hospital

Badalona, Barcelona, Spain

Location

Hospital Universitario de Cruces

Bilbao, Bilbao, Spain

Location

Reina Sofía Hospital

Córdoba, Córdoba, Spain

Location

Josep Trueta Hospital

Girona, Gerona, Spain

Location

Ramón y Cajal Hospital

Madrid, Madrid, Spain

Location

Hospital Clínico Universitario Virgen de la Arrixaca, Murcia

Murcia, Murcia, Spain

Location

Virgen del Rocío Hospital

Seville, Seville, Spain

Location

Virgen Macarena Hospital

Seville, Seville, Spain

Location

Hospital Universitario y Politécnico de La Fe

Valencia, Valencia, Spain

Location

Related Publications (1)

• Zapata-Arriaza E, Medina-Rodriguez M, Moniche Alvarez F, de Alboniga-Chindurza A, Aguilar-Perez M, Ainz-Gomez L, Baena-Palomino P, Zamora A, Pardo-Galiana B, Delgado-Acosta F, Valverde Moyano R, Jimenez-Gomez E, Bravo Rey I, Oteros Fernandez R, Escudero-Martinez I, Vielba-Gomez I, Morales Caba L, Diaz Perez J, Garcia Molina E, Mosteiro S, Castellanos Rodrigo MDM, Amaya Pascasio L, Hidalgo C, Freijo Guerrero MDM, Gonzalez Diaz E, Ramirez Moreno JM, Fernandez Prudencio L, Terceno Izaga M, Bashir Viturro S, Gamero-Garcia MA, Jimenez Jorge S, Rosso Fernandez C, Montaner J, Gonzalez Garcia A. Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial). Trials. 2024 Jan 9;25(1):35. doi: 10.1186/s13063-023-07817-9.

  PMID: 38195586 DERIVED

MeSH Terms

Conditions

Ischemic Stroke

Interventions

Tirofiban; Aspirin

Condition Hierarchy (Ancestors)

Stroke; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Vascular Diseases; Cardiovascular Diseases

Intervention Hierarchy (Ancestors)

Tyrosine; Amino Acids, Aromatic; Amino Acids, Cyclic; Amino Acids; Amino Acids, Peptides, and Proteins; Salicylates; Hydroxybenzoates; Phenols; Benzene Derivatives; Hydrocarbons, Aromatic; Hydrocarbons, Cyclic; Hydrocarbons; Organic Chemicals

Study Officials

• Elena Zapata-Arrizada, PhD

  Virgen del Rocío Hospital, Seville, Spain

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 4
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 29, 2021
• First Posted: February 7, 2022
• Study Start: May 1, 2022
• Primary Completion: March 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: February 18, 2026

Record last verified: 2026-02

Locations

ES (13)